SCHEMBL4448620

SCHEMBL4448620

CNC(=O)[C@@H](NC(=O)c1cc(C(C)C)c(OC)c(C(C)C)c1)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 1/20 0.47
ALDH1A1 P00352 2/20 0.46
TACR3 P29371 1/20 0.45
CTSL P07711 1/20 0.44
CTSS P25774 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
MMP1 P03956 2/20 0.43
MMP2 P08253 2/20 0.43
MMP3 P08254 2/20 0.43
MMP9 P14780 2/20 0.43
MMP14 P50281 2/20 0.43
GPR139 Q6DWJ6 2/20 0.42
MTTP P55157 1/20 0.42
GAA P10253 1/20 0.41
PKM P14618 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GPR88 Q9GZN0 1/20 0.41
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4448626 1.00 S1PR3 (0.47) S1PR3ALDH1A1TACR3CTSLCTSS
SCHEMBL4454637 0.86 ALDH1A1 (0.45) ALDH1A1RXFP1GPR139GAAPKM
SCHEMBL4454641 0.86 ALDH1A1 (0.45) ALDH1A1RXFP1GPR139GAAPKM
SCHEMBL4450275 0.82 TNFRSF1A (0.47) S1PR3ALDH1A1TACR3CTSLCTSS
SCHEMBL4447516 0.82 TNFRSF1A (0.47) S1PR3ALDH1A1TACR3CTSLCTSS
SCHEMBL4447518 0.82 TNFRSF1A (0.47) S1PR3ALDH1A1TACR3CTSLCTSS
SCHEMBL4444765 0.78 S1PR3 (0.56) S1PR3ALDH1A1TACR3MMP1MMP2
SCHEMBL4443040 0.78 S1PR3 (0.53) S1PR3ALDH1A1TACR3MMP1MMP2
SCHEMBL4456188 0.78 MTTP (0.54) S1PR3ALDH1A1TACR3CTSLCTSS
SCHEMBL4456184 0.78 MTTP (0.54) S1PR3ALDH1A1TACR3CTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012010-A1 Amino acid derivatives as calcium channel blockers NEUROMED PHRAMACEUTICALS LTD. (CA) 2009-01-08 US disclosed
US-20090012010-A1 Amino acid derivatives as calcium channel blockers NEUROMED PHRAMACEUTICALS LTD. (CA) 2009-01-08 US disclosed
US-20090012010-A1 Amino acid derivatives as calcium channel blockers NEUROMED PHRAMACEUTICALS LTD. (CA) 2009-01-08 US disclosed
WO-2008141446-A1 AMINO ACID DERIVATIVES AS CALCIUM CHANNEL BLOCKERS NEUROMED PHARMACEUTICALS LTD. (CA) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012010-A1 Amino acid derivatives as calcium channel blockers CACNA1G, CACNA1H, CACNA1I S1PR3 4723/4885ALDH1A1 2335/4885TACR3 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.